Viola Puddinu

Viola Puddinu

Auto-generated profile, based on publicly available information

Viola Puddinu

School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in ACS Nano
Verified
Journal Article
Open access
SHSandra Hočevar
Sandra Hočevar
VPViola Puddinu
Viola Puddinu
LHLaetitia Haeni
Laetitia Haeni
Alke FinkAlke Fink
Alke Fink
JWJulia Wagner
Julia Wagner
CBCarole Bourquin
Carole Bourquin
Engineered gold nanoparticles (GNPs) have become a useful tool in various therapeutic and diagnostic applications. Uncertainty remains regarding the possible impact of GNPs on the immune system. In this regard, we investigated the interactions of polymer-coated GNPs with B cells and their functions in mice. Surprisingly, we observed that polymer-coated GNPs mainly interact with the recently identified subpopulation of B lymphocytes named age-associated B cells (ABCs). Importantly, we also showed that GNPs did not affect cell viability or the percentages of other B cell populations in different organs. Furthermore, GNPs did not activate B cell innate-like immune responses in any of the tested conditions, nor did they impair adaptive B cell responses in immunized mice. Together, these data provide an important contribution to the otherwise limited knowledge about GNP interference with B cell immune function, and demonstrate that GNPs represent a safe tool to target ABCs in vivo for potential clinical applications.

1 June 2021 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
LSLorenzo Spagnuolo
Lorenzo Spagnuolo
VPViola Puddinu
Viola Puddinu
NBNoémie Boss
Noémie Boss
TSThibaud Spinetti
Thibaud Spinetti
AOAnne Oberson
Anne Oberson
CBCarole Bourquin
Carole Bourquin
High mobility group box-1 protein (HMGB1) is an alarmin that, once released, promotes inflammatory responses, alone and as a complex with the chemokine CXCL12. Here we report that the HMGB1-CXCL12 complex plays an essential role also in homeostasis by controlling the migration of B lymphocytes. We show that extracellular HMGB1 is critical for the CXCL12-dependent egress of B cells from the Peyer's patches (PP). This promigratory function of the complex was restricted to the PPs, since HMGB1 was not required for B-cell migratory processes in other locations. Accordingly, we detected higher constitutive levels of the HMGB1-CXCL12 complex in PPs than in other lymphoid organs. HMGB1-CXCL12 in vivo inhibition was associated with a reduced basal IgA production in the gut. Collectively, our results demonstrate a role for the HMGB1-CXCL12 complex in orchestrating B-cell trafficking in homeostasis, and provide a novel target to control lymphocyte migration in mucosal immunity. This article is protected by copyright. All rights reserved

4 August 2026 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
BTBetül Taşkoparan
Betül Taşkoparan
VPViola Puddinu
Viola Puddinu
BBBart Boersma
Bart Boersma
LSLorenzo Spagnuolo
Lorenzo Spagnuolo
HPHélène Poinot
Hélène Poinot
CBCarole Bourquin
Carole Bourquin
High mobility group box protein 1 (HMGB1) is a ubiquitous protein that has multiple functions in the nucleus and cytosol. Following release into the extracellular space, HMGB1 acts as a mediator of inflammation. HMGB1 is overexpressed in many cancers and has both oncogenic and antitumoral effects. Here we investigated the role of HMGB1 expression by cancer cells in the antitumor immune response. Subcutaneous tumors were induced in mice by injection of wild-type or HMGB1-low engineered syngeneic cancer cells. Tumor growth and immune infiltration were assessed, and gene expression was analysed in whole tumors and isolated tumor cells by RNA sequencing analysis. Downregulation of cancer cell-intrinsic HMGB1 prevented tumor growth and reprogrammed the tumor microenvironment into a more inflamed phenotype. Tumor growth was not impacted in immunodeficient mice or in mice deficient in CD8 + T cells, demonstrating that the impact of HMGB1 downregulation on tumor progression was immune-dependent and mediated by CD8 + T cells. Transcriptional profiling showed that HMGB1 low tumors were enriched in immune pathways such as antigen presentation, T-cell receptor and cytokine signalling. Immune activation was robust and detectable in both tumor tissue and secondary lymphoid organs of mice bearing HMGB1 low tumors, but this did not facilitate immune infiltration of wild-type tumors that had been co-injected in the contralateral flank. We propose that tumor cell-intrinsic HMGB1 plays a critical role in modulating the local tumor microenvironment and in limiting anticancer immune responses. Thus, targeting cancer cell-intrinsic HMGB1 may represent a novel approach to improve the outcome of cancer immunotherapy.